GlassScriptPhysician profile
Jan T Rydfors
NPI 1508810763
$3,589.37
in general payments reported to CMS, 2019-2025
32 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,735 · 2020: $286 · 2021: $561 · 2022: $393 · 2023: $251 · 2024: $176 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,289.65 | 2019-2020 | |
| Abbvie INC. | $733.38 | 2019-2023 | Lo Loestrin Fe |
| Pfizer INC. | $180.84 | 2023-2025 | |
| Hologic Sales and Service, LLC | $162.37 | 2019-2025 | Acessa Provu System, Aptima |
| Roche Diagnostics Corporation | $137.51 | 2019-2021 | |
| Myovant Sciences INC. | $105.90 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $70.88 | 2024-2025 | Myfembree |
| Avion Pharmaceuticals | $67.79 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.26 | 2022 | |
| Evofem Biosciences, INC. | $59.23 | 2021-2022 | |
| Stryker Corporation | $53.36 | 2021 | |
| Dexcom, INC. | $48.64 | 2025 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $47.91 | 2020 | |
| Kaleo, INC. | $45.40 | 2019-2021 | |
| Exeltis, USA INC. | $45.11 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.84 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $43.19 | 2023-2024 | Wegovy |
| Ethicon US, LLC | $43.10 | 2024 | Stratafix |
| Minerva Surgical, INC | $40.33 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.06 | 2019 | |
| Cranial Technologies, INC | $33.21 | 2021-2023 | Doc Band |
| Channel Medsystems, INC. | $32.80 | 2022 | |
| Astellas Pharma US INC | $32.53 | 2023 | Veozah |
| Coopersurgical, INC. | $21.17 | 2024 | Paragard T 380a |
| Endo Pharmaceuticals INC. | $21.15 | 2020 | |
| Aspira Women'S Health INC | $16.64 | 2022 | |
| Agiliti Surgical, INC. | $16.47 | 2020 | |
| Axonics, INC. | $15.90 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.74 | 2019 | |
| Sage Therapeutics, LLC | $15.47 | 2021 | |
| Olympus America INC. | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Rydfors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.